Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Smith

Showing results (361-370 of 408) with videos related to

Pageof 41
Sort By:
Breast Cancer Research : BCR|January 2, 2020
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patientsQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Toxins|July 12, 2016
Canopy Venom: Proteomic Comparison among New World Arboreal Pit-Viper VenomsJordan Debono, Chip Cochran, Sanjaya Kuruppu, et al.
Plos One|June 11, 2014
Age-dependent transcriptome and proteome following transection of neonatal spinal cord of Monodelphis domestica (South American grey short-tailed opossum)Norman R Saunders, Natassya M Noor, Katarzyna M Dziegielewska, et al.
Surgical Neurology International|June 3, 2026
Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature reviewNatalie Ivey, Jeff F Zhang, Abigail Zack, et al.
Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.
JNCI Cancer Spectrum|July 31, 2019
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast CancerQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Wellcome Open Research|August 16, 2021
A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER ProjectAura Cecilia Jimenez-Moreno, Cathy Anne Pinto, Bennett Levitan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Breast Cancer Research : BCR|April 3, 2016
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomasElena López-Knowles, Qiong Gao, Maggie Chon U Cheang, et al.
Pageof 41

Showing results (361-370 of 408) with videos related to

Sort By:
Pageof 41
Breast Cancer Research : BCR|January 2, 2020
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patientsQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Toxins|July 12, 2016
Canopy Venom: Proteomic Comparison among New World Arboreal Pit-Viper VenomsJordan Debono, Chip Cochran, Sanjaya Kuruppu, et al.
Plos One|June 11, 2014
Age-dependent transcriptome and proteome following transection of neonatal spinal cord of Monodelphis domestica (South American grey short-tailed opossum)Norman R Saunders, Natassya M Noor, Katarzyna M Dziegielewska, et al.
Surgical Neurology International|June 3, 2026
Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature reviewNatalie Ivey, Jeff F Zhang, Abigail Zack, et al.
Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.
JNCI Cancer Spectrum|July 31, 2019
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast CancerQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Wellcome Open Research|August 16, 2021
A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER ProjectAura Cecilia Jimenez-Moreno, Cathy Anne Pinto, Bennett Levitan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)|February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialDavid Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Breast Cancer Research : BCR|April 3, 2016
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomasElena López-Knowles, Qiong Gao, Maggie Chon U Cheang, et al.
Pageof 41